Skip to main content
NCBI home page
Sexually Transmitted Infections logoLink to Sexually Transmitted Infections
. 1999 Feb;75(1):49–54. doi: 10.1136/sti.75.1.49

Use of antiviral treatment and prophylaxis is unlikely to have a major impact on the prevalence of herpes simplex virus type 2

P J White, G P Garnett
PMCID: PMC1758177  PMID: 10448343

Abstract

BACKGROUND: Genital infection with herpes simplex virus (HSV) is common and can cause severe morbidity, over many years in some cases. Aciclovir provides suppressive therapy but there is debate over the effects of its use on the spread of infection. OBJECTIVES: To explore the influence of the natural history of genital HSV and the impact of antiviral therapy. METHODS: A simple mathematical model of HSV-2 transmission dynamics was developed, and parameter values estimated from published data. RESULTS: The relative durations of the risk of transmitting HSV-2 and the duration of therapy generate a non-linear relation between the duration of antiviral therapy and the reduction in prevalence infection. If there is a wide distribution of risk of HSV-2 transmission over the course of an infection then practicable aciclovir use is unlikely to have any great impact on disease transmission dynamics. CONCLUSIONS: There are still many uncertainties in the transmission dynamics of HSV-2. In particular, infectiousness over the course of an infection requires more detailed exploration. To have a significant impact on the prevalence of HSV-2 aciclovir use would have to be widespread and for a long duration. 




Full Text

The Full Text of this article is available as a PDF (164.1 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Baker D. A. Herpes simplex virus infections. Curr Opin Obstet Gynecol. 1992 Oct;4(5):676–681. [PubMed] [Google Scholar]
  2. Barton SE. All Patients with Recurrent Genital Herpes Should be Offered Suppressive Therapy with Acyclovir. Rev Med Virol. 1996 Jun;6(2):65–66. doi: 10.1002/(SICI)1099-1654(199606)6:2<65::AID-RMV163>3.0.CO;2-S. [DOI] [PubMed] [Google Scholar]
  3. Brunham R. C., Plummer F. A. A general model of sexually transmitted disease epidemiology and its implications for control. Med Clin North Am. 1990 Nov;74(6):1339–1352. doi: 10.1016/s0025-7125(16)30484-9. [DOI] [PubMed] [Google Scholar]
  4. Bryson Y. J., Dillon M., Lovett M., Acuna G., Taylor S., Cherry J. D., Johnson B. L., Wiesmeier E., Growdon W., Creagh-Kirk T. Treatment of first episodes of genital herpes simplex virus infection with oral acyclovir. A randomized double-blind controlled trial in normal subjects. N Engl J Med. 1983 Apr 21;308(16):916–921. doi: 10.1056/NEJM198304213081602. [DOI] [PubMed] [Google Scholar]
  5. Christenson B., Böttiger M., Svensson A., Jeansson S. A 15-year surveillance study of antibodies to herpes simplex virus types 1 and 2 in a cohort of young girls. J Infect. 1992 Sep;25(2):147–154. doi: 10.1016/0163-4453(92)93943-k. [DOI] [PubMed] [Google Scholar]
  6. Corey L., Benedetti J., Critchlow C., Mertz G., Douglas J., Fife K., Fahnlander A., Remington M. L., Winter C., Dragavon J. Treatment of primary first-episode genital herpes simplex virus infections with acyclovir: results of topical, intravenous and oral therapy. J Antimicrob Chemother. 1983 Sep;12 (Suppl B):79–88. doi: 10.1093/jac/12.suppl_b.79. [DOI] [PubMed] [Google Scholar]
  7. Fife K. H. Over-the-counter acyclovir. An idea whose time has come. Sex Transm Dis. 1996 May-Jun;23(3):174–176. doi: 10.1097/00007435-199605000-00002. [DOI] [PubMed] [Google Scholar]
  8. Fleming D. T., McQuillan G. M., Johnson R. E., Nahmias A. J., Aral S. O., Lee F. K., St Louis M. E. Herpes simplex virus type 2 in the United States, 1976 to 1994. N Engl J Med. 1997 Oct 16;337(16):1105–1111. doi: 10.1056/NEJM199710163371601. [DOI] [PubMed] [Google Scholar]
  9. Garnett G. P., Anderson R. M. Sexually transmitted diseases and sexual behavior: insights from mathematical models. J Infect Dis. 1996 Oct;174 (Suppl 2):S150–S161. doi: 10.1093/infdis/174.supplement_2.s150. [DOI] [PubMed] [Google Scholar]
  10. Guinan M. E. Oral acyclovir, palliative therapy for genital herpes: will it change the epidemiology? Sex Transm Dis. 1985 Jan-Mar;12(1):55–56. [PubMed] [Google Scholar]
  11. Handsfield H. H. Acyclovir should not be approved for marketing without prescription. Sex Transm Dis. 1996 May-Jun;23(3):171–173. doi: 10.1097/00007435-199605000-00001. [DOI] [PubMed] [Google Scholar]
  12. Hooper R. R., Reynolds G. H., Jones O. G., Zaidi A., Wiesner P. J., Latimer K. P., Lester A., Campbell A. F., Harrison W. O., Karney W. W. Cohort study of venereal disease. I: the risk of gonorrhea transmission from infected women to men. Am J Epidemiol. 1978 Aug;108(2):136–144. doi: 10.1093/oxfordjournals.aje.a112597. [DOI] [PubMed] [Google Scholar]
  13. Koelle D. M., Benedetti J., Langenberg A., Corey L. Asymptomatic reactivation of herpes simplex virus in women after the first episode of genital herpes. Ann Intern Med. 1992 Mar 15;116(6):433–437. doi: 10.7326/0003-4819-116-6-433. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Koopman J. S., Longini I. M., Jr, Jacquez J. A., Simon C. P., Ostrow D. G., Martin W. R., Woodcock D. M. Assessing risk factors for transmission of infection. Am J Epidemiol. 1991 Jun 15;133(12):1199–1209. doi: 10.1093/oxfordjournals.aje.a115832. [DOI] [PubMed] [Google Scholar]
  15. Lycke E. The pathogenesis of the genital herpes simplex virus infection. Scand J Infect Dis Suppl. 1991;80:7–14. [PubMed] [Google Scholar]
  16. Mertz G. J., Benedetti J., Ashley R., Selke S. A., Corey L. Risk factors for the sexual transmission of genital herpes. Ann Intern Med. 1992 Feb 1;116(3):197–202. doi: 10.7326/0003-4819-116-3-197. [DOI] [PubMed] [Google Scholar]
  17. Mertz G. J., Critchlow C. W., Benedetti J., Reichman R. C., Dolin R., Connor J., Redfield D. C., Savoia M. C., Richman D. D., Tyrrell D. L. Double-blind placebo-controlled trial of oral acyclovir in first-episode genital herpes simplex virus infection. JAMA. 1984 Sep 7;252(9):1147–1151. [PubMed] [Google Scholar]
  18. Mindel A. Is it meaningful to treat patients with recurrent herpetic infections? Scand J Infect Dis Suppl. 1991;80:27–32. [PubMed] [Google Scholar]
  19. Patel R. All Patients with Recurrent Genital Herpes Should not be Offered Suppressive Therapy with Acyclovir. Rev Med Virol. 1996 Jun;6(2):67–69. doi: 10.1002/(SICI)1099-1654(199606)6:2<67::AID-RMV164>3.0.CO;2-J. [DOI] [PubMed] [Google Scholar]
  20. Platt R., Rice P. A., McCormack W. M. Risk of acquiring gonorrhea and prevalence of abnormal adnexal findings among women recently exposed to gonorrhea. JAMA. 1983 Dec 16;250(23):3205–3209. [PubMed] [Google Scholar]
  21. Spruance S. L., Tyring S. K., DeGregorio B., Miller C., Beutner K. A large-scale, placebo-controlled, dose-ranging trial of peroral valaciclovir for episodic treatment of recurrent herpes genitalis. Valaciclovir HSV Study Group. Arch Intern Med. 1996 Aug 12;156(15):1729–1735. [PubMed] [Google Scholar]
  22. Straus S. E., Croen K. D., Sawyer M. H., Freifeld A. G., Felser J. M., Dale J. K., Smith H. A., Hallahan C., Lehrman S. N. Acyclovir suppression of frequently recurring genital herpes. Efficacy and diminishing need during successive years of treatment. JAMA. 1988 Oct 21;260(15):2227–2230. [PubMed] [Google Scholar]
  23. Thomas J. C., Tucker M. J. The development and use of the concept of a sexually transmitted disease core. J Infect Dis. 1996 Oct;174 (Suppl 2):S134–S143. doi: 10.1093/infdis/174.supplement_2.s134. [DOI] [PubMed] [Google Scholar]
  24. Upchurch D. M., Brady W. E., Reichart C. A., Hook E. W., 3rd Behavioral contributions to acquisition of gonorrhea in patients attending an inner city sexually transmitted disease clinic. J Infect Dis. 1990 May;161(5):938–941. doi: 10.1093/infdis/161.5.938. [DOI] [PubMed] [Google Scholar]
  25. Wald A. Beyond efficacy: new issues for HSV antiviral therapy. Genitourin Med. 1997 Apr;73(2):83–84. doi: 10.1136/sti.73.2.83. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Wald A., Koutsky L., Ashley R. L., Corey L. Genital herpes in a primary care clinic. Demographic and sexual correlates of herpes simplex type 2 infections. Sex Transm Dis. 1997 Mar;24(3):149–155. doi: 10.1097/00007435-199703000-00005. [DOI] [PubMed] [Google Scholar]
  27. Wald A., Zeh J., Barnum G., Davis L. G., Corey L. Suppression of subclinical shedding of herpes simplex virus type 2 with acyclovir. Ann Intern Med. 1996 Jan 1;124(1 Pt 1):8–15. doi: 10.7326/0003-4819-124-1_part_1-199601010-00002. [DOI] [PubMed] [Google Scholar]
  28. Wasserheit J. N., Aral S. O. The dynamic topology of sexually transmitted disease epidemics: implications for prevention strategies. J Infect Dis. 1996 Oct;174 (Suppl 2):S201–S213. doi: 10.1093/infdis/174.supplement_2.s201. [DOI] [PubMed] [Google Scholar]
  29. Williams J. R., Nokes D. J., Medley G. F., Anderson R. M. The transmission dynamics of hepatitis B in the UK: a mathematical model for evaluating costs and effectiveness of immunization programmes. Epidemiol Infect. 1996 Feb;116(1):71–89. doi: 10.1017/s0950268800058970. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Sexually Transmitted Infections are provided here courtesy of BMJ Publishing Group

RESOURCES